HER2-Positive Metastatic Breast Cancer: Current Status and Promising Agents on the Horizon

Review the latest data and expert guidance to enhance treatment of your patients with HER2-positive MBC! This comprehensive program features a text-based educational module with downloadable slides and focused clinical commentaries on recent advances and emerging research.

Share

Program Content

Activities

New Agents for HER2+ MBC
How I Plan to Use Trastuzumab Deruxtecan and Tucatinib in My Practice
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: January 21, 2020

Expires: January 19, 2021

CNS Mets in HER2+ MBC
How I Approach CNS Metastases in Patients With HER2-Positive Metastatic Breast Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: April 29, 2020

Expires: April 28, 2021

Activities

HER2+ MBC Slides
HER2-Positive Metastatic Breast Cancer: Current Status and Promising Agents on the Horizon
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: April 13, 2020

Expires: April 12, 2021

Faculty

cover img faculity

Adam M. Brufsky, MD, PhD

Associate Professor
Department of Medicine, Division of Hematology/Oncology
University of Pittsburgh
Pittsburgh, Pennsylvania

cover img faculity

Neelima Denduluri, MD, FASCO

Clinical Assistant Professor
Georgetown University
Washington, DC
Medical Oncologist
Virginia Cancer Specialists
Co-Director, Virginia Cancer Specialists Research Program
Associate Chair, US Oncology Breast Cancer Research Committee
Arlington, Virginia

cover img faculity

Heather McArthur, MD, MPH

Associate Professor
Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Puma Biotechnology, Inc.

Seagen